Migami, Inc. Continues Implementation of Acquisition Strategy regarding Various Proprietary Drug-Delivery Platforms and CMG Manufacturing Facilities

Published: Mar 26, 2009

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Migami, Inc, a publicly traded pharmaceutical and cosmeceutical company (symbol: MIGA) located in Woodland Hills, CA, (“Migami”) is negotiating a Letter of Intent (“LOI”) regarding an Asset Purchase Agreement with respect to Migami’s proposed acquisition of a patented, liposomal drug-delivery platform and certain related manufacturing assets. The liposomal drug-delivery platform being acquired is considered by many to be the next evolutionary step in liposomal technology.

Back to news